Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (411-420 of 666) with videos related to

Pageof 67
Sort By:
Circulation|October 23, 2020
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedFaiez Zannad, João Pedro Ferreira, Stuart J Pocock, et al.
European Journal of Heart Failure|December 11, 2019
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trialMichael Böhm, Jonathan Slawik, Martina Brueckmann, et al.
Diabetes Care|December 6, 2017
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Bernard Zinman, David Fitchett, et al.
Journal of the American Society of Nephrology : JASN|February 9, 2007
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout miceThomas Quaschning, Florian Voss, Katharina Relle, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 24, 2008
OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patientsJoel D Kopple, Alfred K Cheung, Jens Sandahl Christiansen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 29, 2014
Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA RegistryElke Wühl, Karlijn J van Stralen, Christoph Wanner, et al.
Diabetes, Obesity & Metabolism|February 8, 2020
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOMESubodh Verma, Qiuhe Ji, Deepak L Bhatt, et al.
European Heart Journal|December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Bhm, Stefan Anker, Felix Mahfoud, et al.
European Journal of Heart Failure|September 16, 2025
Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-ReducedMichael Böhm, Javed Butler, Amr Abdin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 23, 2012
Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tractElke Wühl, Karlijn J van Stralen, Enrico Verrina, et al.
Pageof 67

Showing results (411-420 of 666) with videos related to

Sort By:
Pageof 67
Circulation|October 23, 2020
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedFaiez Zannad, João Pedro Ferreira, Stuart J Pocock, et al.
European Journal of Heart Failure|December 11, 2019
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trialMichael Böhm, Jonathan Slawik, Martina Brueckmann, et al.
Diabetes Care|December 6, 2017
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Bernard Zinman, David Fitchett, et al.
Journal of the American Society of Nephrology : JASN|February 9, 2007
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout miceThomas Quaschning, Florian Voss, Katharina Relle, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 24, 2008
OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patientsJoel D Kopple, Alfred K Cheung, Jens Sandahl Christiansen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 29, 2014
Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA RegistryElke Wühl, Karlijn J van Stralen, Christoph Wanner, et al.
Diabetes, Obesity & Metabolism|February 8, 2020
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOMESubodh Verma, Qiuhe Ji, Deepak L Bhatt, et al.
European Heart Journal|December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Bhm, Stefan Anker, Felix Mahfoud, et al.
European Journal of Heart Failure|September 16, 2025
Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-ReducedMichael Böhm, Javed Butler, Amr Abdin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 23, 2012
Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tractElke Wühl, Karlijn J van Stralen, Enrico Verrina, et al.
Pageof 67